Global Contrast-Enhanced Mammography Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Contrast-Enhanced Mammography market size was valued at US$ 310 million in 2025 and is forecast to a readjusted size of US$ 465 million by 2032 with a CAGR of 5.9% during review period.
Contrast-Enhanced Mammography (CEM) is a breast imaging technique that builds on standard digital mammography by administering intravenous iodinated contrast and acquiring dual-energy images (low- and high-energy) to reconstruct enhancement/“iodine-only” images. It provides both anatomic detail (similar to conventional mammography) and functional information related to vascularity and permeability, making contrast uptake more conspicuous in many cancers. CEM is particularly relevant for dense breasts, problem-solving in equivocal cases, scenarios where breast MRI is contraindicated or less accessible, and selected pathways such as preoperative evaluation and treatment follow-up. Its clinical and operational value depends on standardized contrast administration and timing, a robust dual-energy imaging chain, and workflow-integrated reading and reporting—so performance gains translate into reproducible, scalable practice. In 2025, global Contrast-Enhanced Mammography production reached approximately 1506 unit and price is about 200 K USD/Unit.The average gross profit margin of this product is 50%.
Sustained demand for earlier detection and higher-throughput breast imaging is pushing radiology departments to adopt solutions that improve sensitivity without disrupting established mammography infrastructure. CEM supports “bringing enhancement capability onto the mammography platform,” leveraging familiar equipment ecosystems and scalable protocols. For providers, CEM can serve as a complementary—or in selected indications, alternative—pathway to breast MRI, helping shorten diagnostic timelines, improve access, and align enhancement imaging with existing mammography workflows, QC frameworks, and staffing models. CEM combines contrast administration, radiation-based imaging, and workflow governance, meaning implementation barriers extend beyond hardware to patient screening (e.g., contrast reactions and renal considerations), timing control, emergency readiness, and cross-team coordination. Clinically, positioning CEM alongside MRI, ultrasound, and tomosynthesis requires clear boundaries and standardized interpretation training to avoid excessive false positives or unnecessary follow-ups. Without strong evidence loops and disciplined QC, hospitals may face uncertainty in defining CEM’s role and sustaining consistent utilization. Demand is shifting from single-test accuracy to pathway-level efficiency—linking CEM with tomosynthesis, targeted ultrasound, biopsy workflows, and preoperative decision-making to enable faster, more streamlined “test-to-decision” cycles. In practice, CEM is often expected to deliver the greatest incremental value in dense breasts, lesion stratification, and MRI-limited populations, with gradual expansion into higher-frequency follow-up and recurrence surveillance scenarios. Meanwhile, radiology leaders increasingly prioritize structured reporting, AI assistance, and cross-site consistency to operationalize quality at scale. The upstream value chain is anchored by “contrast agent & injection systems + dual-energy mammography platform + software/QA components.” Iodinated contrast media and injectors/consumables define administration stability and safety boundaries; dual-energy detectors, x-ray tubes, generators, and compression mechanics drive image consistency and reproducibility; and reconstruction/post-processing software (low-energy images, iodine/enhancement images, artifact suppression, dose management) determines readability and workflow efficiency. Competitive differentiation concentrates on balancing low dose with high contrast, user-friendly reconstruction and reading software, integration with RIS/PACS and structured reporting, and lifecycle QA and service delivery capabilities.
This report is a detailed and comprehensive analysis for global Contrast-Enhanced Mammography market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Contrast-Enhanced Mammography market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (K USD/Unit), 2021-2032
Global Contrast-Enhanced Mammography market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (K USD/Unit), 2021-2032
Global Contrast-Enhanced Mammography market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (K USD/Unit), 2021-2032
Global Contrast-Enhanced Mammography market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (K USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Contrast-Enhanced Mammography
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Contrast-Enhanced Mammography market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hologic, GE Healthcare, Siemens, FUJIFILM, Philips Healthcare, Canon Medical, IMS Giotto, Planmed, Carestream Health, Metaltronica, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Contrast-Enhanced Mammography market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Contrast-Enhanced Mammography product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Contrast-Enhanced Mammography, with price, sales quantity, revenue, and global market share of Contrast-Enhanced Mammography from 2021 to 2026.
Chapter 3, the Contrast-Enhanced Mammography competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Contrast-Enhanced Mammography breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Contrast-Enhanced Mammography market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Contrast-Enhanced Mammography.
Chapter 14 and 15, to describe Contrast-Enhanced Mammography sales channel, distributors, customers, research findings and conclusion.
Contrast-Enhanced Mammography (CEM) is a breast imaging technique that builds on standard digital mammography by administering intravenous iodinated contrast and acquiring dual-energy images (low- and high-energy) to reconstruct enhancement/“iodine-only” images. It provides both anatomic detail (similar to conventional mammography) and functional information related to vascularity and permeability, making contrast uptake more conspicuous in many cancers. CEM is particularly relevant for dense breasts, problem-solving in equivocal cases, scenarios where breast MRI is contraindicated or less accessible, and selected pathways such as preoperative evaluation and treatment follow-up. Its clinical and operational value depends on standardized contrast administration and timing, a robust dual-energy imaging chain, and workflow-integrated reading and reporting—so performance gains translate into reproducible, scalable practice. In 2025, global Contrast-Enhanced Mammography production reached approximately 1506 unit and price is about 200 K USD/Unit.The average gross profit margin of this product is 50%.
Sustained demand for earlier detection and higher-throughput breast imaging is pushing radiology departments to adopt solutions that improve sensitivity without disrupting established mammography infrastructure. CEM supports “bringing enhancement capability onto the mammography platform,” leveraging familiar equipment ecosystems and scalable protocols. For providers, CEM can serve as a complementary—or in selected indications, alternative—pathway to breast MRI, helping shorten diagnostic timelines, improve access, and align enhancement imaging with existing mammography workflows, QC frameworks, and staffing models. CEM combines contrast administration, radiation-based imaging, and workflow governance, meaning implementation barriers extend beyond hardware to patient screening (e.g., contrast reactions and renal considerations), timing control, emergency readiness, and cross-team coordination. Clinically, positioning CEM alongside MRI, ultrasound, and tomosynthesis requires clear boundaries and standardized interpretation training to avoid excessive false positives or unnecessary follow-ups. Without strong evidence loops and disciplined QC, hospitals may face uncertainty in defining CEM’s role and sustaining consistent utilization. Demand is shifting from single-test accuracy to pathway-level efficiency—linking CEM with tomosynthesis, targeted ultrasound, biopsy workflows, and preoperative decision-making to enable faster, more streamlined “test-to-decision” cycles. In practice, CEM is often expected to deliver the greatest incremental value in dense breasts, lesion stratification, and MRI-limited populations, with gradual expansion into higher-frequency follow-up and recurrence surveillance scenarios. Meanwhile, radiology leaders increasingly prioritize structured reporting, AI assistance, and cross-site consistency to operationalize quality at scale. The upstream value chain is anchored by “contrast agent & injection systems + dual-energy mammography platform + software/QA components.” Iodinated contrast media and injectors/consumables define administration stability and safety boundaries; dual-energy detectors, x-ray tubes, generators, and compression mechanics drive image consistency and reproducibility; and reconstruction/post-processing software (low-energy images, iodine/enhancement images, artifact suppression, dose management) determines readability and workflow efficiency. Competitive differentiation concentrates on balancing low dose with high contrast, user-friendly reconstruction and reading software, integration with RIS/PACS and structured reporting, and lifecycle QA and service delivery capabilities.
This report is a detailed and comprehensive analysis for global Contrast-Enhanced Mammography market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Contrast-Enhanced Mammography market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (K USD/Unit), 2021-2032
Global Contrast-Enhanced Mammography market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (K USD/Unit), 2021-2032
Global Contrast-Enhanced Mammography market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (K USD/Unit), 2021-2032
Global Contrast-Enhanced Mammography market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (K USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Contrast-Enhanced Mammography
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Contrast-Enhanced Mammography market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hologic, GE Healthcare, Siemens, FUJIFILM, Philips Healthcare, Canon Medical, IMS Giotto, Planmed, Carestream Health, Metaltronica, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Contrast-Enhanced Mammography market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Dual-energy CEM
- Single-energy Enhanced
- Screening
- Diagnostic Workup
- Pre-op Staging
- Other
- Dedicated CEM Mammography
- Upgrade from Standard System
- Other
- Hospital
- Physical Examination Center
- Other
- Hologic
- GE Healthcare
- Siemens
- FUJIFILM
- Philips Healthcare
- Canon Medical
- IMS Giotto
- Planmed
- Carestream Health
- Metaltronica
- MEDI-FUTURE
- Wandong Medical
- ANKE
- Sino MDT
- Angell
- United Imaging Healthcare
- Alltech Healthcare
- Neusoft Healthcare
- SevenHealth
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Contrast-Enhanced Mammography product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Contrast-Enhanced Mammography, with price, sales quantity, revenue, and global market share of Contrast-Enhanced Mammography from 2021 to 2026.
Chapter 3, the Contrast-Enhanced Mammography competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Contrast-Enhanced Mammography breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Contrast-Enhanced Mammography market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Contrast-Enhanced Mammography.
Chapter 14 and 15, to describe Contrast-Enhanced Mammography sales channel, distributors, customers, research findings and conclusion.
